Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Chatbot coach: could WhatsApp boost HIV knowledge in nigeria?

NCT ID NCT06814041

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a WhatsApp chatbot can improve HIV knowledge in 314 adults recently diagnosed with HIV in Nigeria. Participants use the chatbot for information, reminders, and questions, while a control group receives standard care. The study also looks at effects on resilience and well-being.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 314 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with HIV * ART enrollment: at the day of recruitment or in the subsequent 7 days. But no longer than 30 months prior to enrolment in the study.. * Age ≥ 18 years * Have a personal internet-enabled smartphone with WhatsApp installed * Carry the phone with them at the time of recruitment * Able to understand, read, and write in English (the official language in Nigeria) * Able to understand the information about the study * Provide written informed consent. Exclusion Criteria: * Known pregnancy or ≤3 months postpartum * Persons with suicidal ideation and/or severe mental distress

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Adeoyo Maternity Teaching Hospital

    Ibadan, Oyo, Nigeria

  • Baptist Medical Centre

    Saki, Oyo State, Nigeria

  • Infectious Disease Institute, (IDI) UCH

    Ibadan, Oyo State, Nigeria

  • Our Lady of Apostle Catholic Hospital

    Ibadan, Nigeria

  • Ring Road State Hospital

    Ibadan, Nigeria

  • St. Mary's Catholic General Hospital

    Ibadan, Oyo State, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.